A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

(2010) Angel Casaco et al.   CANCER BIOLOGY & THERAPY

Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation

(2009) A. Talavera et al.   CANCER RESEARCH

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment

(2009) Jaume Capdevila et al.   CANCER TREATMENT REVIEWS

Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer

(2009) Annelies Debucquoy et al.   JOURNAL OF CLINICAL ONCOLOGY

The Impact of Tissue Fixatives on Morphology and Antibody-based Protein Profiling in Tissues and Cells

(2009) Linda Paavilainen et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

(2007) Fernando Rivera et al.   ACTA ONCOLOGICA